Literature DB >> 12711631

A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells.

Yumiko Matsuoka1, Yukitoshi Nagahara, Masahiko Ikekita, Takahisa Shinomiya.   

Abstract

1. Our previous studies revealed that the immunosuppressive agent, FTY720, mainly induces mitochondria-involved apoptosis in some types of cancer cells, since Bcl-2 overexpression prevents the FTY720-induction of apoptotic stimuli. Furthermore, FTY720 induces G0/G1 cell cycle arrest. The present study further examines the correlation between intracellular signaling kinases with FTY720-induced mitochondria-involved apoptosis. 2. Human T cell leukemia Jurkat was exposed to FTY720. Dephosphorylation of Akt occurred in a time- and concentration-dependent manner. FTY720 also induced Bad (Ser(136)) and ribosomal p70S6 kinase (p70(S6k)) (Thr(389)) dephosphorylation. 3. FTY720-induced Akt dephosphorylation was not because of Akt upstream phosphatidylinositol 3'-kinase (PI 3-kinase) pathway inhibition. 4. FTY720 also induced Akt dephosphorylation in human B cell leukemia BALL-1. BALL-1 cells were resistant to FTY720-induced apoptosis. 5. Okadaic acid (OA) inhibited the FTY720-induced dephosphorylation of Akt and p70(S6k), suggesting that FTY720 promotes Ser/Thr protein phosphatase (PP) activity. 6. OA partially inhibited FTY720-induced caspase-3 activation. 7. PP2A or PP2A-like phosphatase was temporarily activated in cells exposed to FTY720. In addition, FTY720 activated purified PP2A (ABC). 8. Overall, the results suggest that FTY720 activated PP2A or PP2A-like phosphatase and dephosphorylated Akt pathway factors resulting in the enhancement of apoptosis via mitochondria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12711631      PMCID: PMC1573783          DOI: 10.1038/sj.bjp.0705182

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site.

Authors:  A Toker; A C Newton
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

Review 2.  Protein kinases as mediators of phosphoinositide 3-kinase signaling.

Authors:  A Toker
Journal:  Mol Pharmacol       Date:  2000-04       Impact factor: 4.436

3.  Protein phosphorylation and protein phosphatases. De Panne, Belgium, September 19-24, 1999.

Authors:  S Zolnierowicz; M Bollen
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

4.  Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia.

Authors:  T C Liu; P M Lin; J G Chang; J P Lee; T P Chen; S F Lin
Journal:  Am J Hematol       Date:  2000-04       Impact factor: 10.047

5.  Evidence that FTY720 induces T cell apoptosis in vivo.

Authors:  Y Nagahara; S Enosawa; M Ikekita; S Suzuki; T Shinomiya
Journal:  Immunopharmacology       Date:  2000-06

Review 6.  Akt signaling: linking membrane events to life and death decisions.

Authors:  B A Hemmings
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

Review 7.  PTEN, a unique tumor suppressor gene.

Authors:  P L Dahia
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

8.  Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms.

Authors:  A Bonni; A Brunet; A E West; S R Datta; M A Takasu; M E Greenberg
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

9.  PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1.

Authors:  P Bruni; A Boccia; G Baldassarre; F Trapasso; M Santoro; G Chiappetta; A Fusco; G Viglietto
Journal:  Oncogene       Date:  2000-06-29       Impact factor: 9.867

Review 10.  The PI3K-PDK1 connection: more than just a road to PKB.

Authors:  B Vanhaesebroeck; D R Alessi
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

View more
  64 in total

1.  Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.

Authors:  Takashi Yoshino; Hiroko Tabunoki; Shigeo Sugiyama; Keitaro Ishii; Seung U Kim; Jun-Ichi Satoh
Journal:  Cell Mol Neurobiol       Date:  2011-04-26       Impact factor: 5.046

Review 2.  Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs.

Authors:  Mitchell K P Lai; Wee Siong Chew; Federico Torta; Angad Rao; Greg L Harris; Jerold Chun; Deron R Herr
Journal:  Neuromolecular Med       Date:  2016-07-08       Impact factor: 3.843

3.  Expression and functional characterization of platelet-derived growth factor receptor-like gene.

Authors:  Feng-Jie Guo; Wei-Jia Zhang; Ya-Lin Li; Yan Liu; Yue-Hui Li; Jian Huang; Jia-Jia Wang; Ping-Li Xie; Guan-Cheng Li
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

Review 4.  Targeting protein serine/threonine phosphatases for drug development.

Authors:  Jamie L McConnell; Brian E Wadzinski
Journal:  Mol Pharmacol       Date:  2009-03-19       Impact factor: 4.436

Review 5.  Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.

Authors:  Gregory T Kunkel; Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  Nat Rev Drug Discov       Date:  2013-08-19       Impact factor: 84.694

6.  The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells.

Authors:  Cuiyan Xin; Shuyu Ren; Wolfgang Eberhardt; Josef Pfeilschifter; Andrea Huwiler
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

7.  Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia.

Authors:  Alejandro Gutierrez; Li Pan; Richard W J Groen; Frederic Baleydier; Alex Kentsis; Jason Marineau; Ruta Grebliunaite; Elena Kozakewich; Casie Reed; Francoise Pflumio; Sandrine Poglio; Benjamin Uzan; Paul Clemons; Lynn VerPlank; Frank An; Jason Burbank; Stephanie Norton; Nicola Tolliday; Hanno Steen; Andrew P Weng; Huipin Yuan; James E Bradner; Constantine Mitsiades; A Thomas Look; Jon C Aster
Journal:  J Clin Invest       Date:  2014-01-09       Impact factor: 14.808

8.  FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.

Authors:  Qing Liu; Xiaobin Zhao; Frank Frissora; Yihui Ma; Ramasamy Santhanam; David Jarjoura; Amy Lehman; Danilo Perrotti; Ching-Shih Chen; James T Dalton; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2007-08-29       Impact factor: 22.113

9.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  Deactivation of sphingosine kinase 1 by protein phosphatase 2A.

Authors:  Renae K Barr; Helen E Lynn; Paul A B Moretti; Yeesim Khew-Goodall; Stuart M Pitson
Journal:  J Biol Chem       Date:  2008-10-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.